Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome.
OBJECTIVE
To evaluate the effects of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome (PCOS).


METHODS
Prospective study.


METHODS
Women with PCOS attending as outpatients of the Endocrine Division, Hospital Durand, Buenos Aires.


METHODS
Twenty-four insulin-resistant women with PCOS.


METHODS
Hormonal evaluations and a standardized oral glucose tolerance test before and after a 3-month trial of 4 mg of rosiglitazone daily.


METHODS
Serum LH, FSH, T, IGF-1, IGFBP-1, IGFBP-3, leptin, 17alpha-hydroxyprogesterone, insulin, and glucose concentrations. The area under insulin curve (AUC-insulin), the HOMA index (insulin resistance), the QUICKI index (insulin sensitivity), and the beta-cell function were calculated. Body mass index (BMI) and the waist/hip ratio were evaluated.


RESULTS
A significant decrease was observed in serum fasting insulin, AUC insulin, HOMA index, beta-cell function, IGF-1, LH, and waist/hip ratio. The QUICKI index and IGFBP-1 increased significantly. Serum sex hormone-binding globulin, androgens, leptin, IGFBP-3, and BMI remained unchanged. Twenty-two of 23 females had their menses restored, and three patients became pregnant. One patient was excluded because she became pregnant at the second month.


CONCLUSIONS
Associated with the decrease in LH, rosiglitazone improved insulin-resistance parameters and normalized the menstrual cycle, which suggests that this drug could improve the endocrine-reproductive condition in insulin-resistant women with PCOS.
Belli
Susana H
SH
Endocrine Division, Hospital Carlos Durand, Buenos Aires, Argentina.
Graffigna
Mabel N
MN
Oneto
Adriana
A
Otero
Patricia
P
Schurman
Leon
L
Levalle
Oscar A
OA
D000293:Adolescent; D000328:Adult; D015992:Body Mass Index; D005260:Female; D005951:Glucose Tolerance Test; D006133:Growth Substances / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007986:Luteinizing Hormone / Q000097:blood; D008598:Menstruation / Q000187:drug effects; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000473:pathology / Q000503:physiopathology*; D011247:Pregnancy; D011446:Prospective Studies; D012098:Reproduction / Q000187:drug effects*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016896:Treatment Outcome
D006133:Growth Substances; D007004:Hypoglycemic Agents; D018970:Insulin-Like Growth Factor Binding Protein 1; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D007334:Insulin-Like Growth Factor I; D007986:Luteinizing Hormone